



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

MYBPH siRNA (m): sc-149732

BACKGROUND

MYBPH (myosin binding protein H), also known as H-protein, is a 477 amino acid protein that is expressed in skeletal muscle, where it is thought to interact with the thick myofilaments in the A-band of myosin. A member of the MyBP family and immunoglobulin superfamily, MYBPH contains two fibronectin type-III domains and two Ig-like C2-type (immunoglobulin-like) domains. The gene encoding MYBPH maps to human chromosome 1, which spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8% of the human genome. Chromosome 1 houses a large number of disease-associated genes, including those that are involved in familial adenomatous polyposis, Stickler syndrome, Parkinson's disease, Gaucher disease, schizophrenia and Usher syndrome. Aberrations in chromosome 1 are found in a variety of cancers, including head and neck cancer, malignant melanoma and multiple myeloma.

REFERENCES

1. Vaughan, K.T., et al. 1993. Human myosin-binding protein H (MYBPH): complete primary sequence, genomic organization, and chromosomal localization. *Genomics* 16: 34-40.
2. Eudy, J.D., et al. 1998. Mutation of a gene encoding a protein with extra-cellular matrix motifs in Usher syndrome type IIa. *Science* 280: 1753-1757.
3. Gruen, M. and Gautel, M. 1999. Mutations in β -myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C. *J. Mol. Biol.* 286: 933-949.
4. Tayebi, N., et al. 2001. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. *Mol. Genet. Metab.* 73: 313-321.
5. Welikson, R.E. and Fischman, D.A. 2002. The C-terminal Ig1 domains of myosin-binding proteins C and H (MyBP-C and MyBPH) are both necessary and sufficient for the intracellular crosslinking of sarcomeric myosin in transfected non-muscle cells. *J. Cell Sci.* 115: 3517-3526.
6. Plasilova, M., et al. 2004. Exclusion of an extracolonic disease modifier locus on chromosome 1p33-36 in a large Swiss familial adenomatous polyposis kindred. *Eur. J. Hum. Genet.* 12: 365-371.
7. Betarbet, R., et al. 2008. Fas-associated factor 1 and Parkinson's disease. *Neurobiol. Dis.* 31: 309-315.
8. Holliday, E.G., et al. 2009. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. *Am. J. Psychiatry* 166: 206-215.
9. Balcárková, J., et al. 2009. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma. *Cancer Genet. Cytogenet.* 192: 68-72.

CHROMOSOMAL LOCATION

Genetic locus: Mybph (mouse) mapping to 1 E4.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

MYBPH siRNA (m) is a pool of 2 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see MYBPH shRNA Plasmid (m): sc-149732-SH and MYBPH shRNA (m) Lentiviral Particles: sc-149732-V as alternate gene silencing products.

For independent verification of MYBPH (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-149732A and sc-149732B.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

MYBPH siRNA (m) is recommended for the inhibition of MYBPH expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor MYBPH gene expression knockdown using RT-PCR Primer: MYBPH (m)-PR: sc-149732-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.